Sacubitril-valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO-SAS study.

Dany JaffuelErika NoguePhilippe BerdagueMichel GalinierPauline FournierMarion DupuisFrédéric GeorgerMarie-Pierre CadarsJean-Etienne RicciNathalie PlouvierFrançois PicardVincent PuelJean-Pierre MalletCarey M SuehsNicolas MolinariArnaud BourdinFrancois Roubille

Published in: ESC heart failure (2021)

In this real-life population, SV treatment for 3 months in SA patients is associated with a significant decrease in AHI. These results support the current guidelines that recommend first an optimization of the HFrEF treatment in patients with HFrEF and central SA. A potential positive airway pressure sparing effect merits further investigation.

Keyphrases

sleep apnea
positive airway pressure
ejection fraction
obstructive sleep apnea
end stage renal disease
chronic kidney disease
prognostic factors
clinical practice
peritoneal dialysis
combination therapy
robot assisted